Latest Biotech News

Argenx agreed to acquire Forte Biosciences in a $2.2 billion all-cash deal, paying $77 per share for the Dallas-based autoimmune specialist. The transaction adds Forte’s lead asset FB102, an...

The FDA raised new questions about Capricor’s deramiocel effectiveness in Duchenne muscular dystrophy, according to briefing materials ahead of a Cellular, Tissue and Gene Therapies Advisory...

Freenome said the FDA has approved its SimpleScreen CRC blood test for colorectal cancer, marking a commercial milestone for blood-based screening using AI and cell-free DNA methylation. The test...

MapLight’s Phase 2 schizophrenia readout delivered overall success but undercut a key differentiation strategy as the once-daily regimen missed the primary endpoint. Twice-daily dosing met the...

Cancer diagnostics startup Pairidex raised $4.89 million in oversubscribed seed financing to advance FusionMRD, an RNA-based droplet digital PCR test for monitoring minimal residual disease in...

Oak Hill Bio is set to reach the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III, a move aimed at funding an investigational rare disease candidate that...

A Nature Communications study unveiled OmniAge, an “aging biomarkers” compendium that integrates multiple omics layers and uses biomarker mapping to investigate biological causality. The work...

Preclinical research reports that CUDC-907 can improve temozolomide activity in glioblastoma by combining dual PI3K and HDAC inhibition. The study focuses on resistance mechanisms that limit...

Two separate leadership developments increased uncertainty across the gene therapy and CAR-T ecosystem. Legend Biotech said CEO Ying Huang abruptly resigned without naming a permanent replacement,...

Sarepta Therapeutics named Michael Severino, formerly CEO of Tessera Therapeutics, as its new chief executive starting Tuesday. The appointment follows Doug Ingram’s planned retirement and comes...

Argenx moved to expand beyond Vyvgart, announcing an all-cash $2.2 billion acquisition of Forte Biosciences. The deal values Forte at $77 per share and is set to close in the third quarter,...

GSK and the GOG Foundation kicked off the first patient in a global phase 3 trial for mocertatug rezetecan in platinum-resistant ovarian cancer. The study, GOG-3132/BEHOLD-Ovarian01 (NCT07286266),...

FDA reviewers raised new efficacy questions about Capricor’s Duchenne muscular dystrophy cell therapy, deramiocel, ahead of an advisory committee meeting. The agency said it could not confirm that...

Freenome said the FDA approved its SimpleScreen CRC, a blood-based colorectal cancer screening test built on cell-free DNA signals. The company, which launched publicly last week, will rely on...

MapLight Therapeutics lost value after disclosing mid-stage results for its schizophrenia drug that were described as positive overall but raised concerns for investors about differentiation. The...

Researchers reported that longitudinal plasma proteomics can identify markers that predict phenoconversion to clinically manifest ALS. In Nature Medicine, investigators analyzed data from the...

Legend Biotech abruptly changed leadership after CEO Ying Huang resigned, with Alan Bash named interim CEO. Legend said a comprehensive search for a permanent replacement is underway and that...

Cancer precision diagnostics startup Pairidex raised $4.89 million in a seed round to advance FusionMRD, an RNA-based droplet digital PCR blood test for monitoring minimal residual disease in...

UC San Diego researchers reported a battery-free wearable patch that continuously monitors levodopa levels in Parkinson’s patients by sampling fingertip sweat. In a Proceedings of the National...

A synthetic DNA industry leader warned that biosecurity screening remains too dependent on voluntary compliance and called for national standards and enforcement. In a commentary, the author...